The Worldwide Market for Prescription Dermatological Drugs, 7th Edition

Attention: There is an updated edition available for this report.
 
   Single User - $3,900
   Corporate License - $7,800
   Site License (one location, 10 users) - $5,000



Loading...
Published Apr 1, 2010 | 250 Pages | Pub ID: KLI2616119

This Kalorama Information report, Worldwide Market for Prescription Dermatological Drugs details the various categories of prescription dermatological drugs, describes the global market and identifies major market factors that may help to shape the market for treatments in the future.

Full Coverage of Nine Prescription Dermatological Drug Segments

The global market for prescription dermatology drugs includes products in the following categories:

  • Prescription Acne and Rosacea Drugs (Benzoyl, Retinoids, Antibiotics, Other)
  • Prescription Antiaging and Photodamage Drugs (Keratolytics, Moisturizers, Retinoids, Sun-screens, Other Agents)
  • Prescription Dermatitis and Seborrhea Drugs(Topical, Systemic, Others)
  • Prescription Fungal Infection Drugs (Topical, Systemic)
  • Prescription Hair Loss and Hair Removal Drugs(Antiandrogens, Androgen Inhibitors, Others)
  • Prescription Hyperpigmentation/Melasma Drugs(Hyperpigmentation/Melasma Agents, Depigmenting Agents)
  • Prescription Psoriasis Drugs (Topical, Systemic, Other)
  • Prescription Skin Cancer Drugs
  • Other Prescription Skin Disorder Drugs(Antiviral Drugs, Antiparasitic Agents)

A Shift to Cosmetic Medications

The pharmaceutical industry is facing a tougher environment in general, due to harder regulations for gaining approvals for mainstream products, economic issues, and a dwindling pipeline of new products. Reliance on blockbuster drugs is all but over, causing a shift of focus for many drug research and development entities. By focusing on cosmetic medications, many manufacturers are realizing less scrutiny from the FDA and a growing need in the niche markets such as dermatology.

This transition will play a role in the future development of the dermatological industry over the forecast period. The global pharmaceutical sector has little choice but to continue expanding through mergers and acquisitions for some time to come.

A Look at Key Trends in Dermatologics

It’s a very dynamic time for the prescription dermatological drug industry. Consolidation, economic times, new technologies and genetic discoveries are among the trends that the industry is seeing, and these are among those analyzed in this report:

  • Economic Downturn: The prescription dermatological drug industry was not immune to the recent economic downturn. Some product categories fared better than others, and these areas are detailed in the report.

  • Cosmetic Dermatologists: The report discusses the debate over a new function for dermatologists in cosmetic procedures.

  • Patient Compliance: Drugs are only effective if patients comply with dosage and time of administration. This is an increasing concern for dermatologists and the industry.

  • Melanoma Survival Rates Falter: While some other cancers have declined in incidence, melanoma remains a growing problem, and new dermatological aids will be in demand.

  • Phosphatidylglycerol and Psoriasis: Researchers now understand more about this lipid and how it may affect psoriasis.

  • New Itch Gene Found: One of many genetic discoveries in the dermatological field recently, the GRPR discovery could have clinical implications soon.

  • New Filler Options: Collagen has been used for twenty years; now two new filler products are being developed and more could be on the way.

  • Consumer Confusion: This is a highly competitive market. With information overload on product choices, its up to the industry to educate.
  • Genetic Link to Psoriasis: Discovery of a possible block to the pathway that activates T cells could change treatment.

  • Rx-to-OTC Switches: Several dermatological products that were prescription are now available OTC.

  • Cosmeceuticals: New personal care products, incorporating antioxidants and polypeptides, go beyond topical moisturizers and anti-wrinkle creams will be a factor in this market.

  • Teledermatology: The taking of and sending of digital pictures for consultation has changed medical practice in this specialty.

  • Reimbursement Issues: The coverage of dermatological drugs can vary be limited.

  • Laser Therapy: While no replacement for prescription dermatological drugs, these technologies may compliment dermatological treatment.

  • Narrowband Ultraviolet B: A new treatment option for actinic prurigo, solar urticaria and cutaneous porphyria has recently become available.

  • Photodynamic Therapy: A possible replacement for surgical excision of primary skin cancer.

  • Synthetic Lipids for Skin Healing: pseudoceramides that are involved in skin cell growth could be used in treating skin diseases in which skin cells grow abnormally

  • Importance of Drug Delivery: Microdermabrasion and novel electrophoretic products are among the delivery systems that could be seen in future products.
  • New Oral Medications for Acne: extended release minocycline, pre-treatment antibiotics and other drugs are an option.

  • Industry Consolidation:The last couple of years has seen a huge consolidation effort going in the pharmaceutical industry. Many top pharmaceutical companies face a deficit in their pipelines and the U.S. Food and Drug Administration is taking a more conservative approach in approving new medicines

  • PYCR1 gene: Scientists may have discovered a link between this gene and skin aging. This discovery could open the door for new discoveries in pharmaceuticals that could mediate the protein in individuals with the gene mutation.
The information and analysis presented in this report are based on extensive interviews with senior management of top companies in the dermatology market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 42 industry executives and product managers to validate and obtain expert opinion on current and future trends in the dermatological market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.

The following companies are profiled in this report:

  • Allergan Inc.
  • Allergan Inamed Corporation
  • Barrier Therapeutics, Inc
  • Bayer AG
  • PharmaDerm Pharmaceuticals, Inc
  • Bristol-Myers Squibb
  • Collagenex (now Galderma) Pharmaceuticals
  • Galderma S.A.
  • Genentech, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson (Janssen Pharmaceutica, Ortho Dermatological, Ortho-McNeil)
  • Medicis Pharmaceutical Corporation
  • Merck & Company, Inc.
  • Mylan Pharmaceuticals, Inc,
  • Novartis Pharmaceuticals Corporation
  • Nycomed Inc.
  • Pfizer, Inc.
  • Q-Med AB
  • Roche Group (F. Hoffmann-La Roche Ltd.)
  • Schering (now Merck)-Plough Corporation
  • Sinclair Pharma Plc.
  • SkinMedica
  • Stiefel Laboratories, Inc.
  • Valeant Pharmaceuticals, Inc.
All market data pertains to the global market at the manufacturers’ level. Data are expressed in current U.S. dollars. The base year for data was 2009. Historical data are provided for each of the years 2007 to 2009, and forecast data are provided for each of the years 2009 through 2014. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2009 base year.
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times